Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis

Am J Trop Med Hyg. 2018 Dec;99(6):1580-1582. doi: 10.4269/ajtmh.18-0387. Epub 2018 Sep 13.

Abstract

Parenteral ivermectin treatment of disseminated strongyloidiasis and hyperinfection is increasing, although not licensed in humans and with limited pharmacokinetic data available. Plasma and postmortem tissue analysis in an human immunodeficiency virus (HIV)/hepatitis C virus-positive man with disseminated strongyloidiasis suggests loading subcutaneous ivermectin doses are required, from which the central nervous system is protected.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Animals
  • Antiparasitic Agents / pharmacokinetics*
  • Autopsy
  • Diarrhea / complications
  • Diarrhea / diagnosis*
  • Diarrhea / drug therapy
  • Diarrhea / pathology
  • Fatal Outcome
  • HIV Infections / complications
  • HIV Infections / diagnosis*
  • HIV Infections / drug therapy
  • HIV Infections / pathology
  • Hepatitis C / complications
  • Hepatitis C / diagnosis*
  • Hepatitis C / drug therapy
  • Hepatitis C / pathology
  • Humans
  • Injections, Subcutaneous
  • Intestinal Pseudo-Obstruction / complications
  • Intestinal Pseudo-Obstruction / diagnosis*
  • Intestinal Pseudo-Obstruction / drug therapy
  • Intestinal Pseudo-Obstruction / pathology
  • Ivermectin / pharmacokinetics*
  • Male
  • Strongyloides / pathogenicity
  • Strongyloides / physiology
  • Strongyloidiasis / complications
  • Strongyloidiasis / diagnosis*
  • Strongyloidiasis / drug therapy
  • Strongyloidiasis / pathology

Substances

  • Antiparasitic Agents
  • Ivermectin